The stock of ArriVent BioPharma Inc (AVBP) has seen a -21.19% decrease in the past week, with a -5.58% drop in the past month, and a 15.27% flourish in the past quarter. The volatility ratio for the week is 8.05%, and the volatility levels for the past 30 days are at 5.67% for AVBP. The simple moving average for the past 20 days is -11.04% for AVBP’s stock, with a 28.66% simple moving average for the past 200 days.
Is It Worth Investing in ArriVent BioPharma Inc (NASDAQ: AVBP) Right Now?
There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AVBP is 19.39M and currently, short sellers hold a 18.23% ratio of that float. The average trading volume of AVBP on November 15, 2024 was 277.52K shares.
AVBP) stock’s latest price update
ArriVent BioPharma Inc (NASDAQ: AVBP)’s stock price has dropped by -11.86 in relation to previous closing price of 31.86. Nevertheless, the company has seen a loss of -21.19% in its stock price over the last five trading days. marketbeat.com reported 2024-11-06 that Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies.
Analysts’ Opinion of AVBP
Many brokerage firms have already submitted their reports for AVBP stocks, with Oppenheimer repeating the rating for AVBP by listing it as a “Outperform.” The predicted price for AVBP in the upcoming period, according to Oppenheimer is $35 based on the research report published on July 22, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AVBP reach a price target of $25. The rating they have provided for AVBP stocks is “Buy” according to the report published on April 30th, 2024.
Jefferies gave a rating of “Buy” to AVBP, setting the target price at $35 in the report published on February 20th of the current year.
AVBP Trading at 0.21% from the 50-Day Moving Average
After a stumble in the market that brought AVBP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.79% of loss for the given period.
Volatility was left at 5.67%, however, over the last 30 days, the volatility rate increased by 8.05%, as shares sank -3.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +5.56% upper at present.
During the last 5 trading sessions, AVBP fell by -21.19%, which changed the moving average for the period of 200-days by +30.30% in comparison to the 20-day moving average, which settled at $31.57. In addition, ArriVent BioPharma Inc saw 40.40% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVBP starting from HILLHOUSE INVESTMENT MANAGEMEN, who purchase 555,555 shares at the price of $18.00 back on Jan 30 ’24. After this action, HILLHOUSE INVESTMENT MANAGEMEN now owns 4,484,672 shares of ArriVent BioPharma Inc, valued at $9,999,990 using the latest closing price.
ORBIMED ADVISORS LLC, the Director of ArriVent BioPharma Inc, purchase 444,444 shares at $18.00 during a trade that took place back on Jan 30 ’24, which means that ORBIMED ADVISORS LLC is holding 1,513,664 shares at $7,999,992 based on the most recent closing price.
Stock Fundamentals for AVBP
The total capital return value is set at -0.29. Equity return is now at value -31.03, with -29.50 for asset returns.
Currently, EBITDA for the company is -74.59 million with net debt to EBITDA at 6.44. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.50.
Conclusion
In conclusion, ArriVent BioPharma Inc (AVBP) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
